RecruitingPhase 3

A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

United States1,440 participantsStarted 2025-05-13

Plain-language summary

Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy.

Who can participate

Age range18 Years

SexMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Has any history of ILD/pneumonitis that required steroid use, except for a history of radiation pneumonitis that did not require steroids
✕. Has current ILD/pneumonitis
✕. Has a clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out

What they're measuring

Overall Survival (OS)

Timeframe: Up to approximately 36 months

Radiographic Progression Free Survival (rPFS)

Timeframe: Up to approximately 36 months

Trial details

NCT IDNCT06925737

SponsorMerck Sharp & Dohme LLC

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2028-06-26

Contact for this trial

Toll Free Number

1-888-577-8839 Trialsites@msd.com

View on ClinicalTrials.gov More Prostate Cancer trials